What is Immunic Therapeutics?
Immunic Therapeutics operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of selective oral immunology therapies. The company focuses on modulating the immune system to treat complex chronic inflammatory and autoimmune diseases. By leveraging a pipeline of small-molecule inhibitors, Immunic aims to provide patients with more convenient and effective treatment alternatives compared to traditional injectable biologics. Its market position is defined by a rigorous commitment to scientific innovation and the pursuit of breakthrough therapeutic solutions that address the underlying mechanisms of disease progression.
How much funding has Immunic Therapeutics raised?
Immunic Therapeutics has raised a total of $1.1B across 4 funding rounds:
Share Placement
$60M
Multiple Rounds
$1B
Share Placement (2022): $60M, investors not publicly disclosed
Stock/Share Issuance (2026): $400M led by Vivo Capital, BVF Partners, TCG Crossover, Avidity Partners, and OrbiMed
Stock/Share Issuance (2026): $400M supported by BVF Partners
Stock/Share Issuance (2026): $200M, investors not publicly disclosed
Key Investors in Immunic Therapeutics
BVF Partners
BVF Partners L.P. is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments with a focus on long-term value creation.
Vivo Capital
Vivo Capital is a global healthcare investment firm headquartered in Palo Alto, managing diverse portfolios across private and public equity as well as venture capital.
TCG Crossover
TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines and supporting innovators in the pharmaceutical and biotechnology sectors.
What's next for Immunic Therapeutics?
With the recent influx of capital, Immunic Therapeutics is expected to prioritize the advancement of its lead clinical assets through late-stage trials. The strategic deployment of these funds will likely focus on scaling manufacturing capabilities, enhancing regulatory engagement, and potentially expanding the scope of its therapeutic pipeline. As the company transitions into a more mature phase of development, the focus will shift toward demonstrating clinical efficacy and preparing for potential commercialization pathways. Investors will be closely monitoring the firm's ability to translate its scientific research into tangible patient outcomes, ensuring long-term value creation in the global biopharmaceutical market.
See full Immunic Therapeutics company page
